Table 2.

Predictors of receiving treatment meeting all 3 quality benchmarks

	Treatment that met all 3 quality benchmarks (Hosmer-Lemeshow P=.19)
Variable	Adjusted OR	95% CI		P
Patient attributes
Age (per each y younger age)	1.02	1.01	1.04	<.001
Pelvic/para-aortic node involved	0.96	0.71	1.31	.80
Hydronephrosis	0.68	0.50	0.94	.02
Treatment attributes
Year of treatment				.24
2000	0.91	0.33	1.51	.86
2001	0.64	0.27	1.67	.30
2002	0.86	0.45	1.15	.66
2003	0.66	0.37	1.37	.14
2004	0.81	0.48	0.81	.42
2005	0.49	0.29	1.33	.01
2006	0.80	0.48	1.28	.39
2007	0.79	0.49	1.55	.34
2008	0.99	0.64	1.45	.98
2009	0.89	0.57	1.38	.60
2010	1.03	0.68	1.55	.90
2011 (referent)	-
Received IMRT	1.18	0.88	1.58	.27
Received HDR brachytherapy	1.77	1.41	2.22	<.001
Sociodemographic attributes
HMO vs other insurance	1.05	0.76	1.44	.78
Employee vs other	0.89	0.72	1.14	.41
Geographic region				.34
Northeast	1.04	0.74	1.47	.82
Midwest	0.94	0.72	1.23	.65
South (referent)	-
West	0.72	0.50	1.04	.08
Population, persons per county >1,000,000 vs ≤1,000,000	0.91	0.68	1.23	.55
No. of radiation oncologists per HSA >10 vs ≤10	1.47	1.11	1.96	.008
No. of internal medicine subspecialists per HSA >100 vs ≤100	0.88	0.66	1.19	.48
No. of gynecologist subspecialists per HSA >10 vs ≤10	0.80	0.60	1.06	.16

Abbreviations: HDR = high-dose rate; HMO = health maintenance organization; HSA = health services area; IMRT = intensity modulated radiation therapy; OR = odds ratio.

Data show predictors of receiving treatment meeting all 3 of the quality benchmarks receipt of brachytherapy, receipt of chemotherapy, and radiation treatment lasting 63 days or less.